AI Product Videos for Nootropic Supplements: Cognitive-Claim Discipline

Cognitive claims are the strictest envelope in supplement marketing, which makes nootropics the category where AI video tools fail most reliably. The ASA rules against "improves focus" and "boosts memory" with consistency the brands often misread as randomness. The EFSA authorised-claims register lists the entire set of permissible cognitive claims for supplements sold in the UK and EU; the list is short, and almost no nootropic blend is on it.

The DTC nootropic brands operating at sustainable scale brief their AI video tools to stay inside the authorised list. The brands that do not are the ones cycling through ad accounts every six to ten weeks.

What follows is the working pattern for nootropic-category AI video, including the three prompt structures that survive review and the per-ingredient claim limits that the brief has to encode.

Why nootropic claims are the strictest envelope

The cognitive function category sits between food supplement law and medicinal product law in a way that no other supplement category does. A claim that an ingredient "supports normal cognitive function" is acceptable if the ingredient is on the EFSA register for that endpoint. A claim that an ingredient "treats brain fog" or "improves cognitive decline" steps over the line into MHRA territory and turns the product into an unlicensed medicinal.

The list of ingredients with authorised cognitive claims under retained EU law is narrow. Iodine, iron, zinc, vitamin B5, B6, B12, and vitamin C each have an authorised claim relating to "normal cognitive function" or "normal psychological function" in the EU register of nutrition and health claims. That is essentially the list. Lion's Mane has no authorised claim. Bacopa monnieri has no authorised claim. Alpha-GPC, citicoline, racetams, and the rest of the modern nootropic stack are not on the register. Some ingredients in popular nootropic blends, racetams in particular, are unapproved medicines in the UK and cannot be sold as supplements at all.

The ASA's enforcement record is consistent. "Sharper focus", "elevated cognition", "boosted brain function" without an authorised cognitive claim attached to a specific cofactor are routinely ruled non-compliant. The category sees more ASA rulings per million units sold than any other supplement segment.

Where AI video tools default to over-claim

A general-purpose video model briefed with "founder of nootropic brand explains why he takes the product" will generate a script. The script will reach for "sharper", "clearer", "deeper focus", "edge", and the rest of the standard nootropic register, because the model has absorbed the language of the category from training data. The training data does not flag which claims were ruled against.

The over-claim is structural rather than incidental. Veo 3.1, Sora 2 Pro, Kling 3.0, and the cheaper hooks-tier models all produce non-compliant scripts on a vanilla nootropic brief. The brief has to constrain the output explicitly with a negative-constraint instruction listing the prohibited claim phrases, and the output still requires line-by-line review.

The same pattern holds across regulated supplement categories. The vitamin-category equivalent is documented in AI video ads for vitamin brands, where the authorised-claims register is wider but the brief discipline is identical.

Three prompt patterns that produce compliant output

These are simplified working briefs, not legal advice. Brands shipping nootropic blends at any meaningful volume should retain a regulatory consultant familiar with both ASA CAP and MHRA borderline classification.

Pattern 1, B-vitamin cofactor framing

Late-30s knowledge worker speaking to camera in a clean home office, mid-afternoon. Wearing a casual button-up, headphones on the desk. Tone is measured, slightly dry. Talks about taking a B-complex with breakfast as part of a routine that supports normal cognitive function during long working days. Mentions specifically that the B-vitamin content is what carries the authorised claim. Does not promise sharper focus, productivity gains, or competitive advantage. Closes with a comment about consistency and adequate sleep mattering more than any single supplement.

Pattern 2, plant-based blend, considered consumer framing

Mid-40s woman in a sunlit kitchen, morning, mug of tea. Talks about why she added a plant-extract blend to her morning routine and what she actually noticed: a sense of calm during heavier weeks, not a transformation. Acknowledges that the specific botanicals do not have authorised health claims and presents the product as a personal preference rather than a clinically validated outcome. Tone is honest and slightly understated. Closes with a measured statement that the routine has worked for her over six months.

Pattern 3, founder framing, single-ingredient product

Brand founder speaking to camera in a clean studio setting, mid-30s. Explains why they formulated the product around a specific micronutrient that has an authorised cognitive claim, what the dose is, and what the claim wording is. Tone is technical and precise. Avoids any reference to enhancement, optimisation, or cognitive performance gains. Closes with a comment that the product is intended for adults whose nutrition may not consistently meet the relevant micronutrient threshold.

The negative-constraint pattern is the consistent thread. AI video tools generate plausible content for whatever they are asked. They do not generate plausible compliance.

Cost framing for nootropic DTC

Nootropic DTC is a smaller category than mainstream supplements, with average order values that compensate for lower unit volume. The cost economics of AI video apply nonetheless. A traditional UGC creator with cognitive-category positioning charges £400 to £1,000 per finished video; the 12 to 20 variants per month required for sustained Meta performance puts the creator-only spend between £5,000 and £20,000 monthly.

AI generation through a vertical-aware platform is in the £50 to £150 range monthly for the same volume. The 30x to 100x cost differential holds. The expensive part of the pipeline is the brief, the compliance review, and the testing infrastructure, not the generation itself. For the per-second pricing across models, Cost per AI video by model in 2026 sets out the breakdown.

The category-specific note: nootropic AOV is typically high enough that hero placements warrant a human creator rate that lower-AOV supplements cannot support. The hybrid pattern, AI for variants and human for hero, is more cost-effective in nootropics than in protein or magnesium.

Cinematography notes for the category

Nootropic ads default to one of three visual registers: the home office knowledge-worker shot, the morning routine kitchen, and the calm-focus studio shot. AI video models handle the first two with comparable competence. The studio shot is harder; the lighting register the category needs (clinical but warm) is at the edge of what generic prompt structures produce.

The brief has to specify lighting explicitly. "Soft directional key from a window or a softbox to camera left, ambient fill at half stop below key, no harsh contrast" produces materially better output across Veo and Sora than "studio lighting". The cinematography brief structure for category-specific scenes is documented in How to write AI video prompts for Veo 3.1.

FAQ

Are AI testimonials permitted for nootropic supplements in the UK?

Yes, within a narrow envelope. The product has to carry an authorised cognitive claim through a specific cofactor, typically a B-vitamin, zinc, iron, or vitamin C, and the script has to use the authorised wording or wording the ASA accepts as equivalent. Most nootropic blend products do not carry an authorised cognitive claim.

Can a brand market a Lion's Mane or Bacopa product as a "focus" supplement in the UK?

No, not without significant qualification. Neither ingredient has an authorised cognitive health claim under retained EU law. Marketing them with cognitive benefit framing is the most common ASA-trigger in the nootropic category. Brands either reformulate to include cofactors with authorised claims or operate outside the cognitive-claim register entirely.

What about US compliance for the same product?

The FTC structure-function envelope is wider but still substantiation-bound. "Supports cognitive function" is acceptable where supported; "improves memory" without clinical evidence is not. Most DTC nootropic brands shipping to both markets default to the UK authorised-claims wording because it transfers cleanly without losing meaningful breadth.

Do AI-generated nootropic ads need to disclose AI generation?

Disclosure expectation is moving toward mandatory across all DTC categories. The CAP code already requires testimonials to be genuine and not misleading; the ASA has signalled increasing scrutiny of synthetic creators in regulated categories. Nootropics, given the category's elevated baseline of regulator attention, is not the category to test the disclosure boundary in.

How does nootropic compliance differ from sleep supplement compliance?

Sleep supplements have a slightly wider authorised-claims register through magnesium and a small number of botanical structure-function claims. Nootropic claims are narrower. The brief discipline is identical; the specific phrasings on the allowlist differ. The sleep-category equivalent is documented in AI testimonial videos for sleep supplements.

For the FTC framework that nootropic supplements operate under in the US, see FTC compliance for supplement ads in 2026.

---

100 free credits to test how Tonic handles cognitive-category briefs without breaching the authorised-claims envelope: tonicstudio.ai/signup?promo=UGC100.